Two Cases of Refractory Wegeners Granulomatosis Successfully Treated with Rituximab
| Autor: | Yoshinari Takasaki, Shigeto Kobayashi, Shinji Morimoto, Hiroshi Hashimoto, Kazuhiko Kaneda, Naoto Tamura, Mika Hirashima, Ran Matsudaira, Masuyuki Nawata, Makoto Ikeda, Michiko Tajima |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Pathology medicine.medical_specialty Adolescent Cyclophosphamide medicine.drug_class Monoclonal antibody Risk Assessment Severity of Illness Index Drug Administration Schedule Antibodies Monoclonal Murine-Derived Refractory immune system diseases hemic and lymphatic diseases Internal Medicine Humans Medicine Adverse effect Anti-neutrophil cytoplasmic antibody Dose-Response Relationship Drug business.industry Remission Induction Granulomatosis with Polyangiitis Antibodies Monoclonal General Medicine medicine.disease Magnetic Resonance Imaging Treatment Outcome Granuloma Prednisone Female Rituximab Tomography X-Ray Computed business Follow-Up Studies Systemic vasculitis medicine.drug |
| Zdroj: | Internal Medicine. 46:409-414 |
| ISSN: | 1349-7235 0918-2918 |
| DOI: | 10.2169/internalmedicine.46.6156 |
| Popis: | Conventional therapy for Wegener's granulomatosis, steroid and cyclophosphamide, fails to control disease activity in some refractory patients and has treatment-related toxicity. B cell depletion therapy using rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effective for certain autoimmune diseases including antineutrophil cytoplasmic antibody (ANCA) -associated systemic vasculitis. We report two refractory cases of Wegener's granulomatosis: one with bronchial and pulmonary involvement and retroorbital granuloma, the other with retroorbital granuloma and hypertrophic pachymeningitis causing severe headache. Rituximab was effective in both cases, with diminished granuloma and reduced ANCA titers, allowing steroids to be tapered. No adverse effects were detected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|